Fulgent Sees Q3 FY23 Sales Of Approximately $65M Vs. Consensus Of $62.84M
Portfolio Pulse from Benzinga Newsdesk
Fulgent Genetics (FLGT) anticipates Q3 FY23 sales to be around $65M, surpassing the consensus estimate of $62.84M.
August 04, 2023 | 3:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Fulgent Genetics (FLGT) expects its Q3 FY23 sales to exceed the consensus estimate, with a projection of approximately $65M.
Fulgent Genetics' projected sales for Q3 FY23 are higher than the consensus estimate. This positive financial outlook could increase investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100